TVARDI THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
TVARDI THERAPEUTICS, INC. (TVRD) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $766.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-05-13
- TVARDI THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- TVARDI THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $241.00K, a 47.84% decline year-over-year.
- TVARDI THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $256.00K, a 33.33% decline year-over-year.
- TVARDI THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $269.00K, a 28.27% decline year-over-year.
- TVARDI THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $766.00K, a 63.08% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.08M, a 45.92% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.42M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $241.00K derived: sum of 2 quarters · filed 2025-03-11 | $497.00K derived: sum of 3 quarters · filed 2025-03-11 | $766.00K 10-K · filed 2025-03-11 |
| 2024-09-30 | $241.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $497.00K derived: sum of 2 quarters · filed 2024-11-14 | $766.00K 10-Q · filed 2024-11-14 | $1.62M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $525.00K 10-Q · filed 2024-08-14 | $1.38M derived: sum of 3 quarters · filed 2025-05-13 | $1.84M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $269.00K 10-Q · filed 2025-05-13 | $1.12M derived: sum of 2 quarters · filed 2025-05-13 | $1.58M derived: sum of 3 quarters · filed 2025-05-13 | $1.97M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $854.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.32M derived: sum of 2 quarters · filed 2025-03-11 | $1.70M derived: sum of 3 quarters · filed 2025-03-11 | $2.08M 10-K · filed 2025-03-11 |
| 2023-09-30 | $462.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $846.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.22M 10-Q · filed 2024-11-14 | $1.59M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $384.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $759.00K 10-Q · filed 2024-08-14 | $1.13M derived: sum of 3 quarters · filed 2025-03-11 | |
| 2023-03-31 | $375.00K 10-Q · filed 2024-05-13 | $742.00K derived: sum of 2 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $367.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.42M 10-K · filed 2025-03-11 | ||
| 2022-09-30 | $1.05M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |